Fig. 8
D16F7 mAb reduces pain in different models of chemotherapy-induced neuropathy. Effect of D16F7 mAb evaluated by (a) Cold plate and (b) Paw pressure tests in a mouse model of oxaliplatin-induced neuropathy after i.t. injection (a, b, n = 6). (c, d) Effect of D16F7 mAb after i.t. administration in vincristine-treated mice stimulated with thermal (c) or mechanical (d) stimuli (n = 6). (e, f) Effect of D16F7 after i.t. administration in paclitaxel-treated mice stimulated with thermal (e) or mechanical (f) stimuli (n = 6). Each value represents the mean ± SEM. **P < 0.01 vs vehicle + vehicle-treated animals; ^P < 0.05 and ^^P < 0.01 vs chemotherapeutic drugs + vehicle-treated animals. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison